RAPT Therapeutics shares surge ~65% premarket on $2.2 bln GSK buyout

Rapt Therapeutics

20/01/2026 09:07

** Shares of RAPT Therapeutics RAPT.O were up 65% in premarket trading on Tuesday, after Britain's GSK GSK.L said it would buy the biotech co for $2.2 bln

** GSK will pay $58 per share in cash, a hefty premium to RAPT's last close

** Deal includes an upfront investment of $1.9 bln

** Acquisition gives GSK global rights to RAPT's experimental food allergy drug ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong

** GSK shares fell about 1% to 1,800.5 pence

** The buyout expands GSK's respiratory, immunology and inflammation pipeline, a key strategic focus

** RAPT had a market value of about $972.65 mln before the announcement

 (Reporting by Rashika Singh in Bengaluru)

 ((Rashika.Singh@thomsonreuters.com;))